点击此处阅读调查报告全文
Our fourth annual report on Hong Kong-listed biotech companies examines how the sector performed during the continuing challenging market conditions of the last full calendar year. Although the number of...more
点击此处阅读调查报告全文
Our third annual report on Hong Kong-listed biotech companies examines how the sector performed during the challenging conditions for capital markets globally over the past 12 months. Although aggregate listing...more
4/25/2023
/ Biotechnology ,
Capital Markets ,
Capital Raising ,
Corporate Governance ,
Foreign Corporations ,
Healthcare ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Life Sciences ,
Listing Rules ,
Popular ,
Publicly-Traded Companies
Our second annual report on Hong Kong-listed biotech companies demonstrates the continued health of the sector. The report provides a comprehensive overview of the market in its current state, examining key data points for...more